| Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial |
|
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT |
|
Blood |
Aplastic Anemia |
| Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation? |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
| Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Severe breakthrough hemolysis during compassionate use of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: managing an emergency |
|
Blood Transfusion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Revisiting Timing and Decision Modeling for Allogeneic Hematopoietic Stem-Cell Transplantation in Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
